www.celltherapeutics.com PR:5 Alexa排名:11545159 Home Targeted Therapies for Blood R

网站综合查询

网站综合信息 www.celltherapeutics.com

标题:
Home | Targeted Therapies for Blood-Re

关键字:
cell lymphomas non hodgkin cti lymphoma leukemia cancers oncology

描述:
CTI BioPharma develops drugs that leverage the its expertise in blood-related cancers to address unm

域名信息
域名年龄:25年8个月29天 注册日期:1998年12月31日 到期时间:2020年12月31日
注册商:NETWORK SOLUTIONS, LLC.

服务器空间
IP:173.203.62.111 同IP网站6个详情
地址:美国德克萨斯州圣安东尼奥市Rackspace Hosting公司

备案信息
备案号:

网站收录SEO数据

搜索引擎
收录量
反向链接
其他

百度
0
0
快照:2015-02-21

Google
222
80
pr:5

雅虎
0

搜搜
17

搜狗
2
评级:2/10

360搜索
0

域名流量Alexa排名

一周平均
一个月平均
三个月平均

Alexa全球排名
-
-
11,545,159

平均日IP
-
-
-

日总PV
-
-
-

人均PV(PV/IP比例)
-
-
-

反向链接
113

dmoz目录收录
Regional/North_America/United_States/Washington/Localities/S/Seattle/Health

流量走势图

域名注册Whois信息

celltherapeutics.com

域名年龄: 25年8个月29天
注册时间: 1998-12-31
到期时间: 2020-12-31
注册商: NETWORK SOLUTIONS, LLC.

获取时间: 2014年04月11日 00:56:11
Domain Name: CELLTHERAPEUTICS.COM
Registrar: NETWORK SOLUTIONS, LLC.
Whois Server: whois.networksolutions.com
Referral URL: http://www.networksolutions.com/en_US/
Name Server: NS1.SAVVIS.NET
Name Server: NS2.SAVVIS.NET
Status: clientTransferProhibited
Updated Date: 2011-11-02
Creation Date: 1998-12-31
Expiration Date: 2020-12-31

>>> Last update of whois database: Thu, 2014-Apr-10 17:00:11 UTC <<<

Welcome to the Network Solutions(R) Registrar WHOIS Server.

The IP address from which you have visited the Network Solutions Registrar WHOIS
database is contained within a list of IP addresses that may have failed
to abide by Network Solutions' WHOIS policy. Failure to abide by this policy can
adversely impact our systems and servers, preventing the processing of
other WHOIS requests.

To see the Network Solutions WHOIS Policy, click on or copy and paste the following
URL into your browser:

http://www.networksolutions.com/whois/index.jhtml

If you feel that you have received this message in error, please email us using the online
form at http://www.networksolutions.com/help/email.jsp with the following information:

Whois Query: celltherapeutics.com
YOUR IP address is 199.180.100.33
Date and Time of Query: Thu Apr 10 13:00:2014-EDT-36
Reason Code: IE

网站头文件(HTTP Header)

HTTP/1.1 302 Found
服务器:Apache
类型:text/html; charset=iso-8859-1
访问时间:2015年02月22日 08:49:02
目标网址:http://www.ctibiopharma.com/
Keep-Alive: timeout=15, max=298
连接:Keep-Alive
设置Cookie:X-Mapping-fjhppofk=6865B4AE8FA71398E2BE22BEB61D3B8C; path=/
文件大小:212

HTTP/1.1 200 OK
服务器:Apache/2.2
类型:text/html; charset=UTF-8
访问时间:2015年02月22日 08:49:02
X-Pingback: http://www.ctibiopharma.com/xmlrpc.php
Link: ; rel=shortlink
Transfer-Encoding: chunked
连接:Keep-Alive
设置Cookie:X-Mapping-dennbkok=67EB44A9D1A6541194E9E94ED4575236; path=/
设置Cookie:cti_visited=1; expires=Wed, 17-Feb-2016 00:49:02 GMT; path=/
网站编码:UTF-8

同IP网站(同服务器)

173.203.62.111 共6个网站 (美国德克萨斯州圣安东尼奥市Rackspace Hosting公司)

Jennerex Therapeutics: B

Home | Targeted Therapie

Ambit Biosciences Corpor

Corcept Therapeutics: Home www.corcept.com

Marina Biotech: Home www.marinabio.com

PTC Therapeutics: Home www.ptcbio.com

其他后缀域名

顶级域名
相关信息

网站首页快照(纯文字版)

抓取时间:2015年02月22日 08:45:21
网址:http://www.celltherapeutics.com/
标题:Home | Targeted Therapies for Blood-Related Cancers | CTI Bi
关键字:cell lymphomas,non hodgkin,cti,lymphoma,leukemia,cancers,oncology
描述:CTI BioPharma develops drugs that leverage the its expertise in blood-related cancers to address unmet medical needs and find therapies that are less toxic.
主体:

Toggle navigationItaliano InvestitoriAbout UsVision & ValuesLeadershipHistoryCollaborationsIn the CommunityCareersMedia GalleryContact CTIProductsPIXUVRI®DevelopmentPipelinePacritinibPixantroneTosedostatPaclitaxel poliglumexPublicationsClinical TrialsClinical Trial OverviewPhysician ResourcesPatient ResourcesInvestorsOverviewNewsStockSEC FilingsAnalyst CoverageEvents & WebcastsAnnual ReportFinancial DetailsCorporate GovernanceInvestor FAQInformation RequestEmail AlertsItaliano InvestitoriSeeing potential in novel compounds.And patients as people.CTI BioPharma uses its hematology/oncology expertise to uncover unique, life-changing therapies that address both unmet clinical needs and the impact on a person's quality of life.Learn moreRecent News
February 3 2015
CTI BioPharma Announces Independent DMC Recommend...
January 12 2015
CTI BioPharma Appoints Alan K. Burnett, M.D. As T...
January 8 2015
CTI BioPharma Announces 2015 Outlook and Recent D...
See More
Pipeline
Track the clinical progress of our novel compounds.
Our Vision
A message from our CEO on CTI's vision and goals.
Patients
Learn about PERSIST-2 and other clinical trials.
Community
See how our employees give back to the community.
About CTIVision & Values
Leadership
History
Collaborations
In the Community
Careers
Media Kit
Contact CTI
Request Information
ProductsPIXUVRI®
DevelopmentPipeline
Pacritinib
Pixantrone
Tosedostat
Paclitaxel poliglumex
Publications
Clinical TrialsClinical Trials Overview
Physician Resources
Patient Resources
Adverse Event Information
InvestorsInvestors Overview
News
Stock
SEC Filings
Analyst Coverage
Events & Webcasts
Annual Report
Financial Details
Corporate Governance
Investor FAQ
Conquering cancer. That's in our blood.
Follow us!
© 2014 CTI BioPharma Corp.
Terms of Use
Privacy Policy
© 2014 CTI BioPharma Corp.
Terms of Use
Privacy Policy
Share
CTI BioPharma and "Conquering cancer. That's in our blood." are trademarks of CTI BioPharma Corp.
You Are Leaving CTI BioPharma
You have selected a link to a third-party website. This link is provided solely as a convenience to you and not as an endorsement by CTI BioPharma of such third-party website. CTI BioPharma is not responsible for and does not make any representations regarding the accuracy of materials on such third-party site.
Continue to the Requested Site
Return to CTI BioPharma
Hello! We are pleased to announce that Cell Therapeutics has changed its name to